Researchers from INCLIVA developed a blood-based test, TAV16, to detect micrometastases in early-stage colon cancer with unprecedented sensitivity. Using ctDNA analysis, it predicts relapse risk more...
The INCLIVA Health Research Institute hosted TERRETA, a forum uniting researchers, clinicians, and patients to advance treatments for rare genetic diseases caused by repeat expansions. The...
Incliva participates in the $6.2 million (€5.2 million) European Rebecca project to address the post-treatment of breast cancer. The project will end in March 2025 and...